# EDGAR Filing Document

**Accession Number:** 0001460702
**File Stem:** 0001493152-25-014622
**Filing Date:** 2025-9
**Character Count:** 2716
**Document Hash:** b4fca1266e6c2ecd4f44c72ced5793bc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-014622.hdr.sgml**: 20260127

**ACCESSION NUMBER**: 0001493152-25-014622

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250923

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Qualigen Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001460702
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 09 Crypto Assets
- **EIN:** 263474527
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 2042 CORTE DEL NOGAL
- **STREET 2:** CARLSBAD
- **CITY:** CALIFORNIA
- **STATE:** CA
- **ZIP:** 92011
- **BUSINESS PHONE:** (760) 918-9165

**MAIL ADDRESS:**
- **STREET 1:** 2042 CORTE DEL NOGAL
- **STREET 2:** CARLSBAD
- **CITY:** CALIFORNIA
- **STATE:** CA
- **ZIP:** 92011

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Qualigen Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20200526

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RITTER PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20090402

**Qualigen Therapeutics, Inc.**

**5857 Owens Avenue, Suite 300**

**Carlsbad, CA 92008**

September 23, 2025

***Via EDGAR***

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Mr. Tyler Howes

---

| | |
|:---|:---|
| **Re:** | **Qualigen Therapeutics, Inc.** |
|  | **Registration Statement on Form S-1** |
|  | **Filed September 16, 2025** |
|  | **File No. 333-290306** |
|  | **Request for Acceleration of Effectiveness** |

---

Dear Mr. Howes:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the "***Registrant***") hereby respectfully requests the U.S. Securities and Exchange Commission (the "***Commission***") to accelerate the effectiveness of its Registration Statement on Form S-1 (File No. 333-290306) (the "***Registration Statement***") to 4:00 p.m. (Eastern Time) on Friday, September 26, 2025, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission.

Please orally confirm the effectiveness of the Registration Statement with Ross Carmel, Esq. of Sichenzia Ross Ference Carmel LLP, counsel to the Company, at (646) 838-1310.

Very truly yours,

---

| | |
|:---|:---|
| **QUALIGEN THERAPEUTICS, INC.** | **QUALIGEN THERAPEUTICS, INC.** |
| By: | */s/ Kevin Richardson II* |
| Name: | Kevin Richardson II |
| Title: | Interim Chief Executive Officer |

---

cc: Ross Carmel, Esq., Sichenzia Ross Ference Carmel LLP